Rytelo (Imetelstat)
First-in-class telomerase inhibitor for transfusion-dependent anemia in lower-risk myelodysplastic syndromes
Quick Facts About Rytelo
Key Takeaways About Rytelo
- First-in-class mechanism: Rytelo is the first approved telomerase inhibitor, targeting the abnormal stem cells that drive anemia in lower-risk MDS
- Restores transfusion independence: In the phase 3 IMerge trial, 40% of patients achieved at least 8 weeks free of red blood cell transfusions
- Given every 4 weeks: Intravenous infusion of 7.1 mg/kg over about 2 hours, with premedication to reduce infusion reactions
- Close blood monitoring required: Thrombocytopenia and neutropenia are common and require complete blood counts before every cycle
- Not for high-risk MDS: Rytelo is approved only for low- to intermediate-1 risk MDS, not for high-risk disease or acute myeloid leukemia
What Is Rytelo and What Is It Used For?
Rytelo (imetelstat) is a prescription medicine used to treat adults with anemia caused by lower-risk myelodysplastic syndromes (MDS) who require regular red blood cell transfusions. It is used when other treatments, particularly erythropoiesis-stimulating agents, have stopped working or are not appropriate. Rytelo is given as an intravenous infusion every four weeks and works by blocking an enzyme called telomerase in abnormal bone marrow cells.
Myelodysplastic syndromes are a group of bone marrow disorders in which the production of blood cells is disrupted. The bone marrow produces abnormal or immature cells that either die before leaving the marrow or function poorly in the circulation. The most frequent and disabling consequence in lower-risk disease is chronic anemia, which leaves patients fatigued, breathless, and dependent on repeated red blood cell transfusions. Transfusion dependence is associated with reduced quality of life, iron overload, and shortened survival, making effective non-transfusion therapies a critical unmet need.
The active substance in Rytelo is imetelstat, a 13-base lipid-conjugated oligonucleotide with a thio-phosphoramidate backbone. It is a rationally designed drug targeting human telomerase, the enzyme responsible for maintaining the protective caps (telomeres) at the ends of chromosomes. Telomerase is abnormally active in malignant stem and progenitor cells in MDS, which is a hallmark of the disease. By inhibiting telomerase, imetelstat selectively suppresses the unhealthy cells that dominate the marrow, allowing healthy hematopoiesis to recover.
Rytelo received regulatory approval based on the pivotal IMerge phase 3 clinical trial, which enrolled adults with very low-, low-, or intermediate-1 risk MDS who required at least four red blood cell transfusion units every eight weeks and who had failed or were ineligible for erythropoiesis-stimulating agents. The study demonstrated a statistically significant improvement in the rate of 8-week and 24-week transfusion independence compared with placebo, supporting its use as a disease-modifying option in this setting.
Approved Indication
Rytelo is indicated for the treatment of transfusion-dependent anemia in adults with low- to intermediate-1 risk myelodysplastic syndromes who:
- Require four or more red blood cell units over eight weeks
- Have not responded to, have lost response to, or are ineligible for erythropoiesis-stimulating agents (ESAs)
It is not approved for higher-risk MDS, acute myeloid leukemia (AML), myeloproliferative neoplasms, or solid tumors outside of clinical trials.
How Rytelo Works
Telomeres are repetitive DNA sequences that cap the ends of each chromosome and shorten with every cell division. When telomeres become critically short, normal cells stop dividing and enter a state of senescence. Cancerous and pre-cancerous cells, however, reactivate telomerase to rebuild their telomeres, allowing unlimited division. This reactivation is a near-universal feature of malignant clones, including those driving ineffective erythropoiesis in MDS.
Imetelstat is complementary in sequence to the RNA template of human telomerase (hTR) and binds to it with high affinity. This binding blocks the enzyme from extending telomeres in the abnormal clonal cells. The malignant stem and progenitor cells, which depend heavily on telomerase activity, progressively lose their proliferative advantage and are eliminated. Normal hematopoietic stem cells, which use telomerase only intermittently, are relatively spared. The result is a rebalancing of the bone marrow ecology in favor of effective erythropoiesis and improved red blood cell output.
Pharmacologically, imetelstat is administered intravenously because its oligonucleotide structure cannot cross the gastrointestinal barrier intact. It distributes to the bone marrow, liver, spleen, and kidneys and is cleared primarily through intracellular metabolism and renal excretion. Because its mechanism directly targets the disease-driving clone rather than symptomatically stimulating erythropoiesis, Rytelo represents a disease-modifying approach that is fundamentally different from erythropoietin-based therapies or lenalidomide.
Rytelo should only be prescribed by hematologists experienced in the management of myelodysplastic syndromes and administered in specialist infusion units capable of managing severe cytopenias and infusion reactions. Treatment decisions should integrate patient fitness, transfusion history, prior therapies, cytogenetics, and comorbidities.
What Should You Know Before Taking Rytelo?
Before starting Rytelo, your hematologist will review your full medical history, baseline blood counts, liver function, infection status, and pregnancy plans. Rytelo must not be used if you are allergic to imetelstat or any excipient, and it requires caution in patients with severe liver disease, existing severe cytopenias, or active infection. Both women and men of reproductive potential must use effective contraception.
Rytelo is a targeted but potent therapy that demands careful pre-treatment evaluation. Because its most common adverse effects involve bone marrow suppression and potentially liver enzyme elevations, the decision to start treatment should be individualized and based on the patient's overall clinical picture. A thorough baseline assessment is essential both to establish suitability and to provide reference values against which future monitoring can be compared.
Contraindications
You must not receive Rytelo if:
- You have known hypersensitivity (severe allergy) to imetelstat or any of the excipients in the formulation
- You have had a prior serious or life-threatening infusion reaction, anaphylaxis, or hypersensitivity syndrome related to imetelstat
If you are unsure about any previous reactions or allergies, discuss them with your doctor before beginning treatment. Your healthcare team will review the list of excipients with you, which include mannitol, sodium chloride, dibasic sodium phosphate, and monobasic sodium phosphate.
Warnings and Precautions
Talk to your hematologist before receiving Rytelo if any of the following apply to you:
- Pre-existing low platelet count: Patients with platelets below 50×109/L at baseline are at increased risk of clinically significant thrombocytopenia during treatment
- Pre-existing low neutrophil count: Baseline neutrophils below 0.5×109/L may increase the risk of severe infections during treatment
- Active infection: Any uncontrolled bacterial, viral, or fungal infection should be treated and resolved before starting Rytelo
- Liver impairment: Severe hepatic dysfunction may increase the risk of transaminase elevations and may warrant dose modification or deferred treatment
- Recent or current bleeding: Active bleeding or a recent major bleed increases the risk of complications from thrombocytopenia
- Prior serious infusion reaction: A history of severe infusion-related reactions to any antineoplastic therapy requires enhanced premedication and monitoring
- Planned surgery: Elective procedures should be scheduled during periods of adequate platelet and neutrophil counts
- Live vaccines: Attenuated live vaccines such as MMR, varicella, yellow fever, and oral polio should generally be avoided during and for several weeks after treatment
Rytelo commonly causes transient but clinically important drops in platelets and neutrophils. Deep cytopenias can precipitate bleeding or serious infections. Your doctor will measure complete blood counts weekly during the first two cycles and before each subsequent dose. Do not miss scheduled blood tests, and report any unusual bruising, bleeding, fever, chills, or shortness of breath immediately.
Tests and Monitoring
Before the first dose and throughout treatment, the following assessments are recommended:
- Complete blood count (CBC) with differential at baseline, weekly for at least the first two cycles, and before every subsequent dose
- Liver function tests (ALT, AST, alkaline phosphatase, bilirubin) at baseline and before each cycle
- Renal function (serum creatinine, eGFR) at baseline and periodically thereafter
- Bone marrow assessment as clinically indicated, particularly if disease progression or transformation to higher-risk MDS or AML is suspected
- Iron studies including ferritin and transferrin saturation to assess iron overload, which is common in transfusion-dependent MDS
- Pregnancy test in women of reproductive potential before starting treatment
Pregnancy and Breastfeeding
Based on findings in animal studies and its mechanism of action, Rytelo may cause embryo-fetal harm when administered to a pregnant woman. Women of reproductive potential must use effective contraception during treatment and for at least one week after the last dose of Rytelo. Male patients with female partners of reproductive potential should also use effective contraception during and for at least one week after the last dose.
- A pregnancy test is performed before treatment begins
- If you become pregnant during treatment, stop Rytelo and contact your doctor immediately
- Do not breastfeed during treatment with Rytelo or for at least one week after the last dose
- Discuss family planning and fertility preservation with your healthcare team before starting therapy
Driving and Using Machines
Rytelo itself has not been shown to directly impair driving ability. However, many patients experience fatigue, dizziness, or headache, particularly in the days following an infusion. You should not drive or operate heavy machinery if you feel tired, lightheaded, or unwell. Infusion reactions, premedication (including antihistamines), and the underlying anemia may all contribute to impaired alertness.
No overall dose adjustment is required solely on the basis of age. However, older patients may have reduced hepatic, renal, or hematologic reserve and often have more concurrent medications. Starting doses are the same as for younger adults, but close monitoring and prompt dose modifications are particularly important in this group.
Children and Adolescents
The safety and efficacy of Rytelo in patients under 18 years of age have not been established. Lower-risk MDS is extremely uncommon in the pediatric population, and no pediatric indication is currently approved.
How Does Rytelo Interact with Other Drugs?
No strong cytochrome P450-mediated drug-drug interactions have been identified with Rytelo, but pharmacodynamic interactions are clinically important. Combining Rytelo with other myelosuppressive, hepatotoxic, or anticoagulant medications can significantly worsen cytopenias, liver toxicity, or bleeding risk. Always give your hematologist a complete and current list of all prescription drugs, over-the-counter medicines, and herbal supplements.
Imetelstat is an oligonucleotide that is cleared largely through intracellular nuclease metabolism and tissue distribution, and it is not a major substrate, inhibitor, or inducer of cytochrome P450 enzymes or common drug transporters at clinically relevant concentrations. As a result, classical pharmacokinetic drug interactions are uncommon. The more important interactions are pharmacodynamic: interactions that amplify the drug's effects on the bone marrow, liver, or clotting system.
Major Interactions
| Interacting Drug / Class | Effect | Recommendation |
|---|---|---|
| Other myelosuppressive cytotoxics (e.g., azacitidine, decitabine, hydroxyurea) |
Additive bone marrow suppression with deeper and more prolonged cytopenias | Avoid concurrent use; if sequential treatment is needed, allow full hematologic recovery between regimens |
| Hepatotoxic medications (e.g., methotrexate, isoniazid, some azoles, acetaminophen excess) |
Increased risk of elevated ALT/AST and clinical hepatotoxicity | Use with caution; monitor liver enzymes more frequently; avoid excessive paracetamol |
| Anticoagulants and antiplatelets (warfarin, DOACs, heparins, aspirin, clopidogrel) |
Increased bleeding risk in the context of treatment-induced thrombocytopenia | Review necessity; monitor platelets and signs of bleeding closely; pause if platelets drop below safe thresholds |
| NSAIDs (ibuprofen, naproxen, diclofenac) |
Platelet inhibition and mucosal injury compound bleeding risk | Prefer paracetamol for pain; use NSAIDs only when essential and with a gastroprotective agent |
| Live attenuated vaccines (MMR, varicella, yellow fever, oral polio, live influenza) |
Risk of disseminated infection from attenuated pathogen during immunosuppression | Avoid during treatment and for at least 3 months after the last dose; use inactivated vaccines where possible |
| Growth factors (G-CSF, erythropoiesis-stimulating agents) |
No pharmacokinetic interaction; may be used supportively in selected cases | Guided by hematology; generally avoided with ongoing Rytelo unless specifically indicated |
Minor and Theoretical Interactions
Imetelstat's oligonucleotide nature means that interactions with highly protein-bound drugs or with other oligonucleotide therapies are theoretically possible but have not been shown to be clinically meaningful at standard doses. Patients often receive concomitant supportive medications such as iron chelators (e.g., deferasirox, deferoxamine), proton pump inhibitors, anti-emetics, and analgesics without notable problems.
Food and Alcohol
Because Rytelo is given intravenously, food does not affect its absorption. However, alcohol can aggravate fatigue, nausea, and liver toxicity and should be limited, particularly on the day of infusion and during the days that follow. Patients with any liver enzyme elevation should avoid alcohol entirely until values have normalized.
Some herbal products (including St. John's wort, high-dose green tea extract, kava, comfrey, and certain weight-loss herbs) may cause hepatotoxicity or affect coagulation. Disclose all supplements to your hematology team, as they can complicate monitoring and increase the risk of adverse events.
What Is the Correct Dosage of Rytelo?
The recommended dose of Rytelo is 7.1 mg/kg of actual body weight, given as an intravenous infusion over approximately 2 hours every 4 weeks. Premedication with a corticosteroid, an antihistamine, and paracetamol is administered about 30 minutes before each infusion. Dose delays and reductions are common during the first cycles to manage cytopenias.
Rytelo dosing is weight-based and is calculated individually for each patient. Administration must follow the detailed reconstitution, dilution, and infusion instructions in the Summary of Product Characteristics (SmPC) or Prescribing Information. The medicine is prepared by hospital pharmacy staff under aseptic conditions and is infused through a dedicated line with an in-line filter of the correct specification.
Premedication
Pre-Infusion Medications (given ~30 minutes before Rytelo)
To reduce the risk of infusion reactions, patients receive the following before every infusion:
- A corticosteroid (e.g., intravenous hydrocortisone 100 mg or equivalent)
- An antihistamine (e.g., diphenhydramine 25–50 mg IV or an equivalent H1 blocker)
- Paracetamol (acetaminophen) 650–1000 mg orally
Adults
Recommended Dose: 7.1 mg/kg IV every 4 weeks
Administered as a 2-hour intravenous infusion using an infusion pump. One treatment cycle is 28 days. Treatment is continued as long as the patient has clinical benefit (reduced or eliminated transfusion need) and the toxicity is manageable. Use actual body weight, not ideal or adjusted weight, for dose calculation.
Dose Modifications for Hematologic Toxicity
| Event | Criteria | Action |
|---|---|---|
| Grade 4 thrombocytopenia | Platelets < 25 × 109/L or bleeding at any grade | Delay dose until recovery; reduce dose by one level on resumption |
| Grade 4 neutropenia | Neutrophils < 0.5 × 109/L lasting > 7 days, or febrile neutropenia | Delay dose until recovery; consider G-CSF support; reduce dose by one level |
| Grade 3 thrombocytopenia with bleeding | Platelets 25–50 × 109/L with clinically significant bleeding | Delay until platelets ≥ 75 × 109/L; reduce dose by one level |
| Recurrent severe cytopenia | Second occurrence after dose reduction | Further dose reduction to next lower level; consider treatment discontinuation if uncontrolled |
| Hepatic toxicity | ALT/AST > 5× ULN or bilirubin > 3× ULN | Withhold Rytelo; investigate cause; on recovery, resume at reduced dose |
| Infusion reaction | Grade 1–2: mild | Slow infusion rate; treat symptomatically; continue with enhanced premedication |
| Severe infusion reaction | Grade 3–4: severe / anaphylaxis | Discontinue Rytelo permanently; manage anaphylaxis per local guidelines |
Dose reduction levels are typically: full dose 7.1 mg/kg → first reduction 5.3 mg/kg → second reduction 3.5 mg/kg. If the patient cannot tolerate 3.5 mg/kg, treatment is discontinued. Exact levels should follow the current product label.
Elderly Patients
No initial dose adjustment is needed based on age alone. However, patients over 75 years of age, those with significant frailty, and those with multiple comorbidities should be monitored with particular vigilance. Infection prevention, bleeding prevention, and fall prevention strategies are especially important in this population.
Renal Impairment
Formal studies in severe renal impairment are limited. In patients with mild to moderate renal impairment (eGFR ≥ 30 mL/min/1.73 m2), no starting dose adjustment is recommended. In patients with severe renal impairment or those on dialysis, Rytelo should be used only if the potential benefit outweighs the risk, with enhanced monitoring.
Hepatic Impairment
Patients with mild hepatic impairment do not require an initial dose adjustment. Data in moderate and severe hepatic impairment are limited; use with caution and consider starting at a reduced dose. Baseline and ongoing liver enzyme monitoring are essential.
Children
Rytelo is not approved for use in patients under 18 years of age. Lower-risk MDS is rare in children, and pediatric pharmacokinetics and safety have not been characterized.
Missed Dose
If a scheduled infusion is missed, contact the hematology team to reschedule as soon as possible. Because Rytelo is given every 4 weeks, occasional short delays are generally manageable and do not require a catch-up infusion. Do not attempt to self-administer or obtain Rytelo outside of the supervised hospital setting.
Overdose
There is no specific antidote for Rytelo overdose. Management is supportive and typically involves intensive monitoring for cytopenias, bleeding, infection, and infusion-related symptoms. Platelet transfusions, red cell transfusions, antibiotics, and growth factor support may be used according to standard supportive care principles. Any suspected overdose should be discussed with a specialist hematologist or poison control center immediately.
What Are the Side Effects of Rytelo?
The most common side effects of Rytelo are thrombocytopenia and neutropenia, which usually develop within the first two cycles and typically recover before the next dose. Other frequent effects include fatigue, headache, elevated liver enzymes, arthralgia, and mild infusion reactions. Serious but less common risks include severe bleeding, febrile neutropenia, sepsis, and clinically significant hepatotoxicity. Call your care team urgently for fever, unusual bleeding, severe fatigue, jaundice, or signs of infection.
As with all antineoplastic medicines, Rytelo can cause a range of side effects. Most are predictable, manageable, and resolve with dose adjustment or supportive care. A minority are serious and require immediate medical attention. Understanding which symptoms to expect, which to monitor, and which to report urgently is a central part of safe treatment.
Contact your hematology team or go to the emergency department immediately if you experience: fever ≥ 38°C (100.4°F) or chills, new or worsening bleeding or bruising, black or bloody stools, severe headache, confusion, chest pain, significant shortness of breath, yellowing of the skin or eyes, or signs of severe infusion reaction (throat tightness, facial swelling, wheeze, rash, or low blood pressure) during or after an infusion.
Frequency of Side Effects
The following side effects have been reported with Rytelo. Frequencies are based on the pivotal IMerge phase 3 clinical trial and post-marketing surveillance.
Very Common (affects more than 1 in 10 patients)
- Thrombocytopenia (low platelets): unusual bleeding, bruising, nosebleeds, petechiae, or prolonged bleeding from small cuts
- Neutropenia (low neutrophils): increased susceptibility to infection, fever, sore throat, mouth ulcers
- Anemia (persisting or worsening): fatigue, pallor, shortness of breath, dizziness
- Fatigue and asthenia
- Headache
- Elevated liver enzymes (ALT, AST, alkaline phosphatase)
- Arthralgia and back pain
- Nausea and constipation
- Peripheral edema (swelling of the ankles or feet)
- Cough
- COVID-19 and other respiratory infections
Common (affects up to 1 in 10 patients)
- Febrile neutropenia: fever in the setting of very low neutrophil counts
- Infusion reactions: flushing, rash, chills, mild hypotension during or shortly after infusion
- Urinary tract infection
- Dizziness and vertigo
- Insomnia
- Diarrhea or abdominal discomfort
- Decreased appetite
- Muscle spasms and myalgia
- Epistaxis (nosebleeds)
- Bronchitis, sinusitis, pneumonia
Uncommon (affects up to 1 in 100 patients)
- Hepatotoxicity: clinically significant liver enzyme elevations, occasional bilirubin rise, usually reversible
- Sepsis and bacteremia secondary to neutropenia
- Major bleeding (gastrointestinal, intracranial, genitourinary)
- Severe infusion reactions requiring treatment interruption
- Tumor lysis syndrome (rare, reported in patients with high disease burden)
Rare (affects up to 1 in 1,000 patients)
- Anaphylaxis to imetelstat or excipients
- Transformation of MDS to higher-risk MDS or acute myeloid leukemia (reflects natural disease biology)
- Severe hepatotoxicity or drug-induced liver injury requiring permanent discontinuation
Hematologic Toxicity Explained
The most frequent and clinically important side effects of Rytelo are cytopenias. Thrombocytopenia typically appears within the first cycle, reaches its nadir around days 14 to 21, and usually recovers before the next scheduled infusion. Neutropenia follows a similar pattern. The majority of cytopenic episodes are manageable with brief dose delays, dose reductions, platelet or red cell transfusions, and, where appropriate, G-CSF support. Most patients do not discontinue treatment because of cytopenias when monitoring and dose modifications are applied promptly.
Persistent deep thrombocytopenia raises the risk of spontaneous bleeding, and persistent deep neutropenia raises the risk of bacterial and fungal infection. Patients should be counseled to avoid contact sports and activities with a high bleeding risk, to practice meticulous oral and skin hygiene, to use soft toothbrushes, and to seek prompt medical attention for any fever, chills, or signs of infection.
Hepatic Monitoring
Elevations in ALT and AST are common but usually mild and asymptomatic. Significant liver enzyme elevations prompt dose delays and investigation for other causes, including viral hepatitis, hepatic iron overload from chronic transfusions, biliary disease, and concomitant hepatotoxic drugs. In most cases, enzyme elevations resolve with temporary interruption of Rytelo and do not lead to permanent discontinuation.
Infusion Reactions
Despite the standard premedication regimen, mild infusion reactions can still occur. They usually manifest as flushing, rash, mild chills, or transient blood pressure changes during or shortly after the infusion and respond quickly to slowing the infusion rate and symptomatic treatment. More serious reactions are uncommon but require immediate interruption and management per local anaphylaxis protocols.
Reporting Side Effects
Patients should keep a symptom diary documenting the timing and severity of side effects relative to each infusion, and report all events to the hematology team. Suspected adverse reactions should also be reported to the relevant national pharmacovigilance authority (e.g., EMA EudraVigilance, FDA MedWatch, MHRA Yellow Card) to help expand the global safety knowledge base for this first-in-class therapy.
How Should You Store Rytelo?
Rytelo vials must be stored in a refrigerator at 2 to 8°C (35 to 46°F) in the original carton to protect from light. Do not freeze. Once reconstituted and further diluted for infusion, Rytelo should be administered within the time limits specified in the prescribing information. Storage and handling are managed by hospital pharmacy staff.
Rytelo is not a medication that patients handle at home. It is shipped, stored, reconstituted, and prepared for infusion by qualified hospital pharmacy staff operating under strict sterility and temperature controls. Nonetheless, understanding the storage requirements helps patients appreciate why infusions must be scheduled precisely and why last-minute rescheduling can be challenging.
Unopened vials are kept refrigerated at 2 to 8°C (35 to 46°F) in their original carton to protect the product from light. The vials must not be frozen. After reconstitution and dilution into a sodium chloride 9 mg/mL (0.9%) solution for infusion, the product is chemically and physically stable for a limited period; exact in-use stability times are specified in the current product label and should be followed strictly. From a microbiological perspective, once the vial is opened, the solution should be used immediately unless opening and dilution have occurred under validated aseptic conditions.
Hospital pharmacies verify the product identity, batch number, expiration date, and visual appearance of every vial before preparation. Any vial that has been frozen, exposed to excessive heat, contaminated, or visibly damaged must not be used. Unused product and waste material must be disposed of according to local requirements for cytotoxic and oligonucleotide pharmaceuticals.
Rytelo should not be used past the expiration date printed on the vial and outer carton. The reconstituted solution is typically colorless to slightly yellow and should not be used if it contains visible particles, discoloration, or signs of microbial contamination.
What Does Rytelo Contain?
The active substance in Rytelo is imetelstat sodium, a 13-base lipid-conjugated oligonucleotide. The formulation also contains mannitol, sodium chloride, dibasic sodium phosphate, and monobasic sodium phosphate as excipients. After reconstitution, the product is diluted in sodium chloride 9 mg/mL (0.9%) solution for infusion.
Each vial of Rytelo contains a sterile, preservative-free lyophilized powder that is reconstituted before use. The active substance is imetelstat, supplied as its sodium salt. Imetelstat is a 13-base palmitoylated oligonucleotide with a thio-phosphoramidate chemistry designed to confer stability against nucleases while allowing high-affinity binding to the RNA template of human telomerase.
Active Ingredient
- Imetelstat (as imetelstat sodium) — available in 47 mg and 188 mg single-dose vials; exact fill volume and concentration after reconstitution are specified in the product label
Excipients (Inactive Ingredients)
The formulation contains the following inactive ingredients, which support stability, tonicity, and pH during storage and administration:
- Mannitol — bulking and cryoprotectant agent
- Sodium chloride — tonicity adjustment
- Dibasic sodium phosphate — buffering agent
- Monobasic sodium phosphate — buffering agent
Diluent
For final infusion, the reconstituted solution is further diluted in sterile sodium chloride 9 mg/mL (0.9%) solution for injection, according to the instructions in the Summary of Product Characteristics. No other diluents or co-administered solutions should be used in the same line.
Sodium Content
Each dose of Rytelo contains sodium from both the active substance formulation and the saline diluent. The total sodium load per infusion is generally well tolerated, but should be considered in patients on strict sodium-restricted diets and in those with congestive heart failure or advanced renal disease.
Appearance and Packaging
Rytelo is supplied as a white to off-white lyophilized powder in a single-dose glass vial with a rubber stopper and a flip-off seal. Each carton contains a single vial. After reconstitution, the solution is colorless to slightly yellow and essentially free of visible particles.
Marketing Authorization and Regulatory History
Rytelo was developed by Geron Corporation and received its first regulatory approval from the U.S. Food and Drug Administration in 2024 for the treatment of transfusion-dependent anemia in lower-risk MDS following failure of erythropoiesis-stimulating agents. Additional approvals and appraisals by the European Medicines Agency, the UK MHRA, and other national authorities have followed. Imetelstat represents the first approved agent in the telomerase inhibitor class.
Frequently Asked Questions About Rytelo
Rytelo (imetelstat) is a first-in-class telomerase inhibitor approved for adults with transfusion-dependent anemia due to lower-risk myelodysplastic syndromes (MDS) who have not responded to, or are no longer responding to, erythropoiesis-stimulating agents. It binds with high affinity to the RNA template of human telomerase, suppressing the abnormal stem and progenitor cells that drive ineffective erythropoiesis, and allowing healthy red blood cell production to recover. This targeted mechanism makes Rytelo a disease-modifying therapy rather than simply a symptomatic treatment for anemia.
Rytelo is administered as an intravenous infusion over approximately two hours every four weeks at a hospital or specialist infusion unit. The dose is 7.1 mg/kg of actual body weight. Premedication with a corticosteroid, an antihistamine, and paracetamol (acetaminophen) is given about 30 minutes beforehand to reduce the risk of infusion reactions. Each cycle is 28 days long, and treatment continues as long as benefit outweighs toxicity.
The most common side effects are thrombocytopenia (low platelets) and neutropenia (low neutrophils), which usually develop within the first two cycles and typically recover before the next dose. Patients may also experience fatigue, headache, elevated liver enzymes, arthralgia, COVID-19 or other infections, and mild infusion reactions. Serious side effects include severe cytopenias with bleeding or infection, and require close laboratory monitoring with complete blood counts and liver function tests.
Rytelo must not be given to patients with known hypersensitivity to imetelstat or to any of its excipients. It is not recommended during pregnancy or breastfeeding because of potential embryo-fetal toxicity. It should be used with caution in patients with pre-existing severe thrombocytopenia, uncontrolled infection, significant hepatic impairment, or active bleeding. It is not approved for children, for higher-risk MDS, or for acute myeloid leukemia outside of clinical research.
Treatment with Rytelo is continued for as long as the patient benefits clinically, meaning that red blood cell transfusion independence is maintained or improved and toxicity remains manageable. In the pivotal IMerge phase 3 trial, 40% of patients achieved at least 8 weeks of red cell transfusion independence and 28% achieved 24 weeks or more. Treatment is stopped if the disease progresses, cytopenias become unmanageable despite dose modifications, or unacceptable toxicity develops.
No. Rytelo is not a cure for myelodysplastic syndrome. It is a disease-modifying therapy designed to reduce or eliminate the need for red blood cell transfusions and to improve quality of life in patients with lower-risk MDS. The only potentially curative option for MDS is allogeneic hematopoietic stem cell transplantation, which is usually reserved for higher-risk disease and eligible younger patients. Rytelo has not yet been shown to affect overall survival or progression to acute myeloid leukemia in a definitive manner.
Unopened vials of Rytelo are stored in a refrigerator at 2 to 8°C (35 to 46°F) in the original carton to protect from light. The powder must not be frozen. Once reconstituted and diluted in sodium chloride 0.9% infusion solution, Rytelo should be administered within defined time limits according to the prescribing information. Storage and handling are managed by hospital pharmacy staff, and patients do not need to handle the medicine themselves.
Inactivated vaccines, such as seasonal inactivated influenza, pneumococcal, COVID-19, and non-live shingles vaccines, are generally recommended when your counts allow an adequate response, and ideally should be timed early in the cycle. Live attenuated vaccines (MMR, varicella, yellow fever, oral polio, live intranasal influenza) should be avoided during treatment and for at least three months after the last dose. Always coordinate vaccination plans with your hematology team.
References
- U.S. Food and Drug Administration (FDA). RYTELO (imetelstat) — Prescribing Information. Geron Corporation; approved June 2024. Available at: accessdata.fda.gov. Accessed December 2025.
- European Medicines Agency (EMA). Rytelo (imetelstat) — European Public Assessment Report. Available at: ema.europa.eu/en/medicines/human/EPAR/rytelo. Accessed December 2025.
- Platzbecker U, Santini V, Fenaux P, et al. Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2024;403(10423):249-260. doi:10.1016/S0140-6736(23)01724-5
- Steensma DP, Fenaux P, Van Eygen K, et al. Imetelstat Achieves Meaningful and Durable Transfusion Independence in High Transfusion-Burden Patients With Lower-Risk Myelodysplastic Syndromes. J Clin Oncol. 2021;39(1):48-56.
- Fenaux P, Platzbecker U, Mufti GJ, et al. Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes. N Engl J Med. 2020;382(2):140-151. (context for comparative therapies)
- Greenberg PL, Stone RM, Al-Kali A, et al. NCCN Clinical Practice Guidelines in Oncology: Myelodysplastic Syndromes. National Comprehensive Cancer Network. Latest version 2025.
- Fenaux P, Haase D, Santini V, et al. Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32(2):142-156.
- Harrington L, Robinson MO. Telomerase and disease: genetics of ribosomopathies and related disorders. Cold Spring Harb Perspect Biol. 2022;14(8):a040778.
- World Health Organization (WHO). Classification of tumours of haematopoietic and lymphoid tissues. 5th edition. WHO; 2022.
- Anatomical Therapeutic Chemical (ATC) Classification Index. WHO Collaborating Centre for Drug Statistics Methodology. Available at: whocc.no. Accessed December 2025.
About the Editorial Team
This article was written and reviewed by the iMedic Medical Editorial Team, comprising licensed specialists in hematology, oncology, pharmacology, and clinical medicine. Our content follows the GRADE evidence framework and is based on peer-reviewed research, international clinical guidelines (EMA, FDA, NCCN, ESMO, WHO), and established medical standards.
Every article undergoes a rigorous multi-step review: initial research by medical writers, clinical accuracy verification by specialist physicians, editorial review for clarity and accessibility, and final approval by the Medical Review Board.
We prioritize Level 1A evidence from systematic reviews and randomized controlled trials. All medical claims are referenced to peer-reviewed sources. No commercial funding influences our content.
Last medically reviewed: | Published: | Read our editorial standards